3rd Annual ADC Analytical Development Summit

Kongressthemen
The updated ICH Q14 guidance from the FDA revising analytical procedures used for release and stability testing has shown higher product quality expectations from regulatory agencies. As analytical studies become an indispensable requirement to progress the antibody-drug conjugate space forward, so has the need for rigorous analytical methodologies that ensure product quality ahead of regulatory submissions.

Kongressorganizer (PCO)
Hanson Wade Group

Anmerkungen
Brochure: https://go.evvnt.com/2097379-3?pid=4832

Speakers: Allison Torgesen, Quality Control Director, Bolt Biotherapeutics, Amit Katiyar, Senior Director - Late Stage Biologics, Exelixis, and more

https://go.evvnt.com/2097379-2?pid=4832

Frau Jessica Durston